Serum lipoprotein (a) and atherosclerotic changes in hemodialysis patients

Mahmoud Rafieian-Kopaei¹, Hamid Nasri²*

¹Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran
²Department of Internal Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran

Abstract

Introduction: Lipoprotein (a) [Lp(a)] is considered as a risk factor for coronary atherosclerotic disorder and an increase in plasma Lp(a) concentration is usually seen in patients with kidney failure.

Objectives: We aimed in this study to evaluate the impact of plasma Lp(a) level on early changes of atherosclerotic vessels in stable hemodialysis (HD) patients.

Patients and Methods: In this clinical study 61 patients (50 non-diabetic (F=20 M=30) and 11 diabetic HD patients), receiving maintenance hemodialysis were included and serum Lp(a) was measured. B-mode ultrasonography of carotid intima-media thickness (cIMT) was also determined.

Results: The mean ±SD of patients Lp(a) was 58.5±19 mg/dL. The mean ±SD of diabetic patients’ Lp(a) was 62±12 mg/dL and for non-diabetic ones was 57.7±20 mg/dL. In this study the thickening of Intima-media complex in diabetic group was more than non-diabetics, and no significant difference was found of Lp(a) between diabetic and non diabetic HD patients. There was a significant positive association between serum Lp(a) and cIMT.

Conclusion: Accelerated atherosclerosis seen in diabetic hemodialysis patients. Lp(a) might have an important role in progression of atherosclerosis to accelerate progressive atherosclerosis in these patients.

Implication for health policy/practice/research/medical education:

Accelerated atherosclerosis seen in diabetic hemodialysis patients. Lipoprotein (a) might have an important role in progression of atherosclerosis to accelerate progressive atherosclerosis in these patients.

Please cite this paper as: Rafieian-Kopaei M, Nasri H. Serum lipoprotein (a) and atherosclerotic changes in hemodialysis patients. J Renal Inj Prev 2013; 2(2): 47-50. DOI: 10.12861/jrip.2013.17

Introduction

Lipoprotein (a) is a macromolecule consisting a glycoprotein apolipoprotein (a) that is linked to apolipoprotein B-100 on LDL core (1). Its concentration is primarily determined genetically (2). Epidemiological studies have illustrated that, in high level, it is an independent risk factor for atherosclerotic coronary disorders (1,2). In renal failure, the plasma concentration of lipoprotein (a) [Lp(a)] may increase dramatically (1-3). However, the increase in Lp(a) level in these patients usually is not due to inherent. Kidneys might have an important role in Lp(a) metabolism (1-3). Indeed in beginning of chronic renal failure, Lp(a) starts to increase when glumerular filtration rate (GFR) reaches below 70 ml/min, (1-3), and dialysis procedure will be not able to reduce serum Lp(a) level. Irrespective of mechanisms which may be involved in increasing the Lp(a) level, this lipid might be a contributing factor in high frequency of atherosclerotic disorder observed in HD patients (1-3).

Atherosclerosis has been shown to be accompanied by some changes in arterial structure. Subtle structural changes such as arterial intima-media thickening (IMT) may occur early in the atherosclerotic disorder process (3,4). Using B-mode
ultrasonography for evaluating early arteriosclerosis is noninvasive and safe to study superficial vascular districts, like carotid artery (3). Therefore, ultrasonic evaluation of carotid artery for intima-media thickness may help identifying patients at risk for cardiovascular diseases (3). Carotid-IMT (cIMT) measurements are also strongly related to the extent of atherosclerosis in other vascular districts (3,4).

There is a significant association between conventional risk factors and increased arterial wall thickness (3,4), however, the effects of Lp(a) on IMT in hemodialysis patients is not fully understood.

**Objectives**
In this study we, therefore, aimed to evaluate the effects of plasma Lp(a) level on early structural atherosclerotic vascular changes in a group of HD patients under maintenance hemodialysis.

**Patients and Methods**

**Patients**
This cross-sectional study was conducted on sixty-one patients on maintenance hemodialysis. Cigarette smoking, taking lowering drugs, recent MI, vascular diseases, body mass index (BMI) more than 25, as well as active or chronic infection were considered as exclusion criteria. Lp(a) was measured in patients by enzyme immunoassay (ELISA) method using immuno-biological laboratories (IBL) kits (Germany).

**Assessment of arterial intima-media thickening**
Carotid sonography (Honda-Hs-2000 Sonograph with 7.5 MHZ linear probe) was done at the end of diastolic phase by a sonologist who was blind to history or lab data of patients. For examination, patients were placed in supine position with neck hyperextension and rotation of head to facilitate the performance of the procedure. The sites of measurements were at the distal common carotid artery, first proximal internal carotid artery and area of bifurcation. IMT was measured at the plaque free areas (3,4). IMT was considered as the distance from leading edge of lumen-intima interface of the far wall to the leading edge of the media-adventitia interface of the far wall (3,4). IMT more than 0.8 mm was considered abnormal (3-5).

**Ethical issues**
(1) The research followed the tenets of the Declaration of Helsinki; (2) informed consent was obtained; (3) the research was approved by the institutional review board.

**Statistical analysis**
For analysis we measured the mean of right and left cIMTs. Data were expressed as Mean±SD. Comparison between groups was done using Mann-Whitney U test, Kruskal Wallis test and Fisher’s exact test. To evaluate the correlations we used spearman's rho test, partial correlation test with adjustment for age, also Phi & Cramer's V test and Eta test were used. All statistical analysis was performed using SPSS 11 (SPSS Inc., Chicago, IL, USA). P of less than 0.05 was considered as significant.

**Results**
The total patients were 61 (male=38 and female=23), consisting of 11 diabetic hemodialysis patients (F=3 and M=8) and 50 non diabetic hemodialysis patients (M=30 and F=20). Table 1 shows the means±SD of patients’ data. The mean age of the patients was 46.5±16 years. The duration in which patients were on HD was 32±31 months. Serum Lp(a) of patients was 58.5±19 mg/dl. Serum Lp(a) of diabetic and nondiabetic groups were 62±12 mg/dl and 57.7±20 mg/dl, respectively. The cIMT of diabetic and non diabetic patients were 1.3±0.3 mm and 1±0.25 mm, respectively. All HD patients were hypertensive from stage one to stage three. In this study there was not any significant difference for age or duration of hemodialysis treatment between male and female subjects (p>0.05). No significant difference for DM was also seen between two sexes (p>0.05). There was not also significant difference for duration of hemodialysis treatment or ages of the patients between diabetic and non diabetic patients (p>0.05). The difference between diabetic and non diabetic groups was not significant for serum Lp(a), too (p>0.05). However, there was a significant difference for cIMT between diabetic and non-diabetic patients (p<0.05). Statistical analysis on cIMT with partial correlation test (after adjustment for age) revealed no correlation between cIMT and duration of hemodialysis treatment (p>0.05). Statistical analysis on Lp(a) showed a significant positive correlation between cIMT and lipoprotein(a) (r=0.330, p=0.008).

**Discussion**
In this study there was more thickening of intima-media complex in diabetic patients compared to non-diabetic ones. However, no significant difference was found for lipoprotein (a) between diabetic and non-diabetic HD patients. Pascasio et al. observed a lot of vascular plaques in patients suffering from Uremia. He concluded that the process of advance atherosclerosis should be started with initiating of renal failure. They suggested that HD treatment might not be a potential factor for accelerating atherosclerosis. In addition, they concluded that, progression of atherosclerosis should be related to atherogenic factors which exist before regular dialysis (5). To investigate, IMT of 45 dialysis patients, Damjanovic and colleagues found higher mean cIMT in HD patients compared to control group. They found a positive association between cIMT and certain risk factors for atherosclerosis (duration of dialysis, lipid parameters and age) (6). The correlation of IMT and age of the patients or duration of hemodialysis in HD patients was investigated, by Shoji and Hojs. In their studies, they did not find any relationship between IMT and duration of HD (7-9). They concluded that hemodialysis patients might develop
advanced atherosclerosis in the carotid arteries compared with normal subjects (7-9). In agreement with our findings, in a study on 24 dialysis patients, Savage and colleagues noted the correlation between age and cIMT (10). Likewise, Kato et al. in a study observed a significant correlation between IMT and age on 219 hemodialysis patients (11). Similarly, Baldassarre and colleagues in a study on 100 patients, showed higher values of cIMT in hypercholesterolemic patients with plasma Lp(a) levels >30 mg/dL than in those with lower levels. They concluded that elevated plasma levels of lipoprotein (a) might be considered as additional independent factor associated with thickening of carotid artery in subjects with severe hypercholesterolemia but not in those with moderate hypercholesterolemia or normal patients (12). Finally, Raitakari and colleagues in a study on 241 healthy subjects found no association between cIMT and serum Lp(a) level, however, significant positive correlation could be seen between IMT and total Cholesterol, LDL-C, LDL/HDL ratio, TG or age (13).

In the present study there was a significant positive association between serum Lp(a) and cIMT. Although, the extraordinary high mortality of HD patients are due to cardiovascular disease, there are some interests toward nontraditional atherosclerotic cardiovascular diseases risk factors such as Lp(a) which are high in HD patients . This needs more attention because of its effects on acceleration of rapid progressive atherosclerosis seen in HD patients.

### Table 1. Patients’ data

|                     | Total patients | Diabetic group | Non-Diabetic group |
|---------------------|----------------|----------------|--------------------|
|                     | Mean±SD        | Min | Max | Mean±SD        | Min | Max | Mean±SD        | Min | Max |
| Age (years)         | 46.5±16        | 15  | 78  | 57±16          | 27  | 78  | 47.8±16        | 15  | 78  |
| Duration of hemodialysis (months) | 32±31          | 2   | 108 | 22.6±22.4      | 3   | 60  | 34±33          | 2   | 108 |
| cIMT (mm)           | 1.06±0.3       | 0.50 | 1.70 | 1.3±0.3       | 0.8  | 1.70 | 1±0.25         | 0.50 | 1.60 |
| Lp(a) (mg/dL)       | 58.5±19        | 25  | 154 | 62±12          | 40  | 85  | 57.7±20        | 25  | 154 |

### Conclusion

Diabetic HD patients have more accelerated atherosclerosis. Lp(a) as a nontraditional factor in progression of atherosclerosis can have a more important role in acceleration of rapid progressive atherosclerosis observed in these patients.

### Acknowledgments

We would like to thank research deputy of Shahrekord University of Medical Sciences for financial support and Dr. M. Mowlaei (sonologist) for carotid ultrasonographies.

### Authors’ contributions

HN designed and performed the research. MRK wrote some parts of paper. MRK edited the draft. HN prepared the final draft.

### Conflict of interests

The authors declared no competing interests.

### Ethical considerations

Ethical issues (including plagiarism, misconduct, data fabrication, falsification, double publication or submission, redundancy) have been completely observed by the authors.

### Funding/Support

None.

### References

1. Aggarwal HK, Jain D, Lathar M, Yadav RK, Sawhney A. Lipoprotein-A and carotid intima media thickness as cardiovascular risk factors in patients of chronic kidney disease. *Ren Fail* 2010; 32: 647-52.
2. Topciu Shufta V, Begolli L, Kryeziu E. Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis. *Bosn J Basic Med Sci* 2010; 10: 19-25.
3. Ishibashi S. Lipoprotein (a) and atherosclerosis. *Arterioscler Thromb Vasc Biol* 2001; 21: 1-2.
4. Nasri H, Baradaran A. Association of serum lipoprotein (a) with ultrasonographically determined early atherosclerotic changes in the carotid and femoral arteries in kidney transplanted patients. *Transplant Proc* 2004; 36: 2683-6.
5. Pascasio L, Blanco F, Giorgini A, Galli G, Corri G, Panzetta G. Echo color Doppler imaging of carotid vessels in hemodialysis patients: evidence of high levels of atherosclerotic lesions. *Am J kidney Dis* 1996; 28: 713-20.
6. Damjanovic T, Dimkovic N. Dialysis as a risk factor for development of atherosclerosis. *Med Pregl* 2003; 56: 17-21.
7. Shoji T, Emoto M, Tabata T, kimoto E, Shinohara

http://journalrip.com
K, Maekawa K, et al. Advanced atherosclerosis in predialysis patients with chronic renal failure. *Kidney Int* 2002; 61; 2187-92.

8. Hojs R. Carotid intima-media thickness and plaques in hemodialysis patients. *Artif Organs* 2000; 24: 691-5.

9. Hojs R, Hojs-fabjant, Balon BP. Atherosclerosis in patients with end-stage renal failure prior to initiation of hemodialysis. *Ren fail* 2003; 25: 17-54.

10. Savage T, Clarke AL, Giles M, Tomson CRV, Raine AG. Calcified plaque is common in the carotid and femoral arteries of dialysis patients without vascular disease. *Nephrol Dial Transplant* 1998; 13: 2004-12.

11. Kato A, Takako T, Yukitaka M, Hiromishi K, Akira H. Impact of carotid atherosclerosis on long-term mortality in chronic hemodialysis patients. *Kidney Int* 2003; 64: 1472.

12. Baldassarre D, Tremoli E, Franceschini G, Michelagnolis, Sirtori CR. Plasma lipoprotein (a) is an independent factor associated with carotid wall thickening in severely but not moderately hypercholesterolemic patients. *Stroke* 1996; 27: 1044-9.

13. Raitakari OT, Adams MR, Celermajer DS. Effect of Lp(a) on the early functional and structural changes of atherosclerosis. *Arterioscler Thromb Vase Biol* 1999: 990-995.